11/28/2016 - AbbVie Inc. was downgraded to "neutral" by analysts at Citigroup.
The 52-week high is at -1.61% and the 52-week low stands at 20.62%. The company reported $1.20 earnings per share for the quarter, meeting the consensus estimate of $1.20.
AbbVie (NYSE:ABBV) last issued its earnings results on Friday, January 27th. Vetr downgraded shares of AbbVie from a "strong-buy" rating to a "buy" rating and set a $69.24 target price for the company.in a report on Tuesday, January 17th. The Company's year to date (YTD) performance is now positive at 5.34%. Zacks' EPS averages are a mean average based on a survey of research firms that cover AbbVie.
Lebenthal Asset Management LLC raised its position in shares of AbbVie Inc (NYSE:ABBV) by 0.7% during the fourth quarter, according to its most recent filing with the SEC.
The Company has 868.00 million shares outstanding and 856.03 million shares were floated in market. The firm earned $6.78 billion during the quarter, compared to analysts' expectations of $6.92 billion. The net profit margin for AbbVie Inc. stands at 23.20%. During the same quarter in the previous year, the business earned $1.13 EPS.
William Blair Lowers Cardinal Health Inc (CAH) to Market Perform
Following the completion of the sale, the chairman now owns 682,225 shares of the company's stock, valued at $52,688,236.75. COPYRIGHT VIOLATION WARNING: This story was first published by Markets Daily and is the sole property of of Markets Daily.
Basically, a price target is an individual analyst's projection on the future price of a stock. Leerink Swann Initiates Coverage On the company's stock to Market Perform on 10/18/16 with no specific Price Target. Finally, BMO Capital Markets reiterated a "hold" rating and set a $63.00 price target on shares of AbbVie in a research report on Wednesday, March 22nd. Societe Generale raised AbbVie from a "sell" rating to a "hold" rating in a research note on Wednesday, March 22nd. (ABBV) where 3 analyst have rated the stock as Strong Buy, 6 analysts said it's a Buy, 11 rated the stock as Hold, 1 analysts reported Underperform and 0 analysts gave their recommendations as Sell. They now have a Dollars 65 price target on the stock. If you are viewing this piece on another publication, it was stolen and reposted in violation of USA and global copyright and trademark laws. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & global trademark & copyright legislation. The legal version of this story can be read at https://www.themarketsdaily.com/2017/04/26/lebenthal-asset-management-llc-purchases-1026-shares-of-abbvie-inc-abbv-updated.html.
Lowe's Companies, Inc.'s (LOW) witnessed a gain of 0.84% in recent trading period with closing price of $ 84.17. The stock is now trading with a distance of 20-Day Simple Moving Average (SMA20) of -0.55%. The firm has a 50-day moving average of $65.04 and a 200-day moving average of $62.21. The stock has a market cap of $103.06 billion, a P/E ratio of 17.81 and a beta of 1.57. AbbVie Inc has a 1-year low of $55.06 and a 1-year high of $68.12.
The firm also recently announced a quarterly dividend, which will be paid on Monday, May 15th. Stockholders of record on Thursday, April 13th will be paid a dividend of $0.64 per share. FNB Bancorp's dividend has April 28, 2017 as record date.
The stock now has its Annual Dividend of $2.56 and an annual Dividend Yield of 3.94 Percent. AbbVie's payout ratio is presently 70.52%. Following the completion of the sale, the vice president now directly owns 16,706 shares of the company's stock, valued at $1,090,734.74. The transaction was disclosed in a document filed with the SEC, which is available at this link. 2,311 AbbVie Inc (NYSE:ABBV) shares with value of $143,031 were sold by HURWICH THOMAS A. The stock was sold at an average price of $65.29, for a total value of $335,068.28. Following the completion of the sale, the insider now directly owns 147,415 shares of the company's stock, valued at approximately $9,620,302.90. The disclosure for this sale can be found here. The stock traded at a volume of 5.3 million shares. The stock of AbbVie Inc (NYSE:ABBV) has "Equal-Weight" rating given on Wednesday, June 8 by Morgan Stanley. Tracking most recent quarter period, Price to book (P/B) ration is at 22.53 and Price to cash per share ration is at 16.27. Moreover, Shaker Investments Llc Oh has 2.27% invested in the company for 39,820 shares.
The number of shares now held by investors is 1.59 Billion. St. Louis Trust Co boosted its position in AbbVie by 0.6% in the third quarter. (ABBV) is a good investment, however if the market is weaker then it could suggest that the shares are undervalued. Finally, City Holding Co. increased its stake in AbbVie by 1.5% in the third quarter. RNC Capital Management LLC now owns 638,336 shares of the company's stock valued at $40,260,000 after buying an additional 17,996 shares during the period.
Comments